Immune Checkpoints in Recurrent Pregnancy Loss: New Insights into a Detrimental and Elusive Disorder.

T-cell activity endometrium immune activity immune tolerance placentation pregnancy recurrent pregnancy loss

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Aug 2023
Historique:
received: 16 07 2023
revised: 17 08 2023
accepted: 21 08 2023
medline: 11 9 2023
pubmed: 9 9 2023
entrez: 9 9 2023
Statut: epublish

Résumé

Recurrent pregnancy loss (RPL) refers to two or more miscarriages before 20 weeks gestation. Its prevalence is 1-2%; its pathogenesis remains unexplained in more than 50% of cases, in which the cause is thought to be abnormal immune activity during placentation leading to a lack of pregnancy-induced immune tolerance. It is unknown whether immune activity is deranged in the endometrium of women with RPL. We studied the gene expression and the quantitative tissue protein levels of three immune checkpoints (CD276, which enhances cytotoxic T-cell activity, cytotoxic T-lymphocyte-associated antigen-4 [CTL-4], which reduces Th1 cytokine production, and lymphocyte activation gene-3 [LAG-3], which shows suppressive activity on Tregs and CD4+ T-cells) in endometrial samples from 27 women with unexplained RPL and in 29 women with dysfunctional uterine bleeding and previous uneventful pregnancies as controls. RNA isolation, real-time PCR, protein isolation, and ELISA were performed. CD276 gene expression and protein tissue levels were significantly lower in the endometrium of the RPL group than in the controls, whereas both CTL-4 and

Identifiants

pubmed: 37685876
pii: ijms241713071
doi: 10.3390/ijms241713071
pmc: PMC10488095
pii:
doi:

Substances chimiques

Transcription Factors 0
Abatacept 7D0YB67S97
CD276 protein, human 0
B7 Antigens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Int Immunol. 1999 Nov;11(11):1745-52
pubmed: 10545478
J Immunol. 1999 Mar 1;162(5):2748-53
pubmed: 10072520
J Exp Med. 1992 Aug 1;176(2):327-37
pubmed: 1380059
Fertil Steril. 2015 Oct;104(4):927-931
pubmed: 26207958
Immunol Lett. 2017 Apr;184:43-50
pubmed: 28216262
Am J Reprod Immunol. 2011 Oct;66(4):270-8
pubmed: 21481059
Am J Transplant. 2014 Sep;14(9):1985-91
pubmed: 25098238
Int J Mol Sci. 2019 Oct 26;20(21):
pubmed: 31717776
Reprod Sci. 2014 May;21(5):640-7
pubmed: 24177713
Fertil Steril. 1996 Jun;65(6):1135-40
pubmed: 8641486
Clin Exp Immunol. 2011 May;164(2):265-74
pubmed: 21352204
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Eur J Immunol. 2005 Jul;35(7):2081-8
pubmed: 15971272
J Reprod Immunol. 1998 Apr;38(1):63-73
pubmed: 9616878
PLoS One. 2015 Jun 11;10(6):e0130126
pubmed: 26065426
FASEB J. 1996 May;10(7):769-76
pubmed: 8635694
J Assist Reprod Genet. 2017 Apr;34(4):425-430
pubmed: 28188592
Fertil Steril. 2016 Jan;105(1):106-10
pubmed: 26456229
Am J Gastroenterol. 2002 Dec;97(12):3160-5
pubmed: 12492204
Transplantation. 2007 Dec 15;84(11):1500-6
pubmed: 18091527
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
Eur J Immunol. 1996 May;26(5):1180-6
pubmed: 8647185
Annu Rev Immunol. 2000;18:367-91
pubmed: 10837063
Fertil Steril. 2010 Mar 1;93(4):1234-43
pubmed: 19338986
Fertil Steril. 2015 Jun;103(6):1579-86.e1
pubmed: 25935494
Immunity. 2004 Oct;21(4):503-13
pubmed: 15485628
Cancer Sci. 2016 Sep;107(9):1193-7
pubmed: 27297395
Tumour Biol. 2016 Mar;37(3):2961-71
pubmed: 26411671
Nat Rev Immunol. 2017 Aug;17(8):469-482
pubmed: 28627518
J Clin Invest. 2007 Nov;117(11):3383-92
pubmed: 17932562
Annu Rev Immunol. 2001;19:565-94
pubmed: 11244047
Exp Cell Res. 2013 Jan 1;319(1):96-102
pubmed: 22999863
Front Immunol. 2020 Mar 24;11:458
pubmed: 32265918
J Reprod Immunol. 2013 Mar;97(1):140-6
pubmed: 23432880
J Obstet Gynaecol Res. 2021 Feb;47(2):689-697
pubmed: 33274569
Fertil Steril. 2011 Mar 1;95(3):1156-8
pubmed: 21030015
Reprod Biol Endocrinol. 2017 Mar 4;15(1):16
pubmed: 28259137
Placenta. 2004 Jan;25(1):1-8
pubmed: 15013633
Science. 1995 Oct 27;270(5236):630-3
pubmed: 7570020
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Mol Hum Reprod. 2004 May;10(5):347-53
pubmed: 14997000
Cancer Chemother Pharmacol. 2018 Feb;81(2):245-253
pubmed: 29299639
N Engl J Med. 1998 Jul 30;339(5):285-91
pubmed: 9682040
Trends Immunol. 2015 Feb;36(2):63-70
pubmed: 25582039
Am J Reprod Immunol. 2017 Aug;78(2):
pubmed: 28224680
J Immunol. 2004 Aug 15;173(4):2500-6
pubmed: 15294965
Neurol Clin. 2012 Aug;30(3):877-88
pubmed: 22840794

Auteurs

Luca Marozio (L)

Department of Surgical Sciences, Obstetrics and Gynecology 1, University of Turin, Via Ventimiglia 1, 10126 Turin, Italy.

Anna Maria Nuzzo (AM)

Department of Surgical Sciences, University of Turin, Via Ventimiglia 1, 10126 Turin, Italy.

Eugenio Gullo (E)

Department of Surgical Sciences, Obstetrics and Gynecology 1, University of Turin, Via Ventimiglia 1, 10126 Turin, Italy.

Laura Moretti (L)

Department of Surgical Sciences, University of Turin, Via Ventimiglia 1, 10126 Turin, Italy.

Emilie M Canuto (EM)

Department of Surgical Sciences, Obstetrics and Gynecology 1, University of Turin, Via Ventimiglia 1, 10126 Turin, Italy.

Annalisa Tancredi (A)

Department of Surgical Sciences, Obstetrics and Gynecology 1, University of Turin, Via Ventimiglia 1, 10126 Turin, Italy.

Margherita Goia (M)

Unit of Pathology, Department of Medical Sciences, University of Turin, Via Santena 7, 10126 Turin, Italy.

Stefano Cosma (S)

Department of Surgical Sciences, Obstetrics and Gynecology 1, University of Turin, Via Ventimiglia 1, 10126 Turin, Italy.

Alberto Revelli (A)

Department of Surgical Sciences, Obstetrics and Gynecology 2, University of Turin, Via Ventimiglia 1, 10126 Turin, Italy.

Alessandro Rolfo (A)

Department of Surgical Sciences, University of Turin, Via Ventimiglia 1, 10126 Turin, Italy.

Chiara Benedetto (C)

Department of Surgical Sciences, Obstetrics and Gynecology 1, University of Turin, Via Ventimiglia 1, 10126 Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH